The Geneva University Hospital is taking part in a trial to test a promising treatment for long-covid.
A Geneva biopharmaceutical company, GeNeuro, has developed an antibody which targets the persistence of inflammation after an infection.
The trial will last for 6 months and is due to start early next year. Recruitment for test subjects has already begun. Researchers are hoping for around 200 volunteers.
The results should be known in the second half of next year.
The company says long-covid is associated more with the Delta variant of covid – it seems to be less common with Omicron.
Swiss rail head under guard
How did Switzerland strike US deal
Health insurance premiums drive debt
Zurich Christmas Market backtracks on cash
Federal move to allow Sunday openings
International interest in fondue championship
